NCT00936611View on ClinicalTrials.gov

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

PHASE2CompletedINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

November 30, 2012

Conditions

Waldenstrom's Macroglobulinemia

Interventions

DRUG

LBH589

Trial Locations (2)

80220

Rocky Mountain Cancer Centers, Denver

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER